Skip to content

Zevra Therapeutics, Inc. ZVRA Balance Sheet Statement

TTM Q1 '26TTM Q4 '25TTM Q3 '25TTM Q2 '25TTM Q1 '25
$95.6M+156%$62.41M+84.7%$54.44M+0.7%$47.71M+21.5%$37.34M-12.9%
$105.02M+315%$128.61M+260%$145.07M+311%$154.9M+1,449%$25.29M+156%
$22.1M+75.1%$23.26M+121%$16.84M+116%$18.27M+104%$12.62M+51.9%
$2.38M-94.1%$13M-69.3%$23.12M-43.9%$31.15M-5.4%$40.57M+74.2%
$229.97M+182%$223.01M+159%$225.12M+126%$226.34M+272%$81.57M+29.7%
$430K+1.9%$489K+37.4%$488K-19.6%$599K-11.7%$422K-39.3%
$4.7M0.0%$4.7M0.0%$4.7M0.0%$4.7M$4.7M
$6.11M-90.9%$6.42M-90.7%$6.74M-90.5%$7.05M$67.38M
$278.58M+61.3%$284.73M+59.8%$270.12M+41.0%$256.28M+77.5%$172.71M+14.2%
$11.69M-34.4%$11.6M-54.4%$11.07M-54.7%$15.84M-22.5%$17.82M-21.8%
$47.03M+74.3%$39.28M+15.3%$26.11M-24.3%$28.83M-5.3%$26.98M-9.8%
$0-100%$61.93M+4.1%$61.31M+4.1%$60.69M+4.1%$60.09M
$8.16M-93.8%$11.12M-92.0%$136.95M+12.5%$139.05M+24.2%$131.69M+28.5%
$6K+20.0%$6K+20.0%$6K+20.0%$6K+50.0%$5K+25.0%
-$384.17M+24.4%-$422.06M+16.5%-$434.23M+7.5%-$433.68M+0.6%-$508.39M-22.1%
$205.8M+402%$154.66M+290%$133.17M+90.9%$117.23M+261%$41.02M-16.0%
$278.58M+61.3%$284.73M+59.8%$270.12M+41.0%$256.28M+77.5%$172.71M+14.2%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

What are Zevra Therapeutics, Inc.'s total assets?
Zevra Therapeutics, Inc. (ZVRA) holds $278.6M in total assets, up 61.3% year over year.
How much debt does Zevra Therapeutics, Inc. have?
Zevra Therapeutics, Inc. carries $1.1M in total debt against $205.8M of shareholders' equity, a debt-to-equity ratio of 0.01.
How much cash does Zevra Therapeutics, Inc. have?
Zevra Therapeutics, Inc. holds $95.6M in cash and equivalents.
Can Zevra Therapeutics, Inc. cover its short-term obligations?
Its current ratio is 4.89 — current assets exceed current liabilities.
Where does Zevra Therapeutics, Inc.'s balance sheet data come from?
Every line is extracted from Zevra Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.